Update On the Myriad Appeal and Announcing a Public Forum On the USPTO 101 Guidelines

By | PharmaPatents | April 17, 2014

Myriad has appealed the district court decision that denied its motion for a preliminary injunction against Ambry Genetics Corp. According to a report in Bloomberg BNA Life Sciences Law & Industry Report™, on April 14 , 2014, the Federal Circuit denied Myriad’s motion to expedite proceedings, but it is still possible that this Myriad appeal will be argued and decided by the end of this calendar year.

The USPTO Glossary Pilot Program

By | PharmaPatents | April 2, 2014

In a Federal Register Notice published March 27, 2014, the USPTO announced a Glossary Pilot Program that will offer expedited examination to new patent applications in certain technology areas that include a glossary of terms that meets certain formal requirements.

USPTO Releases Examiner Post-”Myriad” Training Slides – Points to Ponder

The United States Patent and Trademark Office (USPTO) published its examiner training materials (Training Materials) for applying ”2014 Procedures For Subject Matter Eligibility Analysis Of Claims Reciting Or Involving Laws of Nature/Natural Principles, Natural Phenomena, And/Or Natural Products” (Guidance)…